Lantern Pharma’s (LTRN) N-hydroxy-N(methylacylfulvene)urea was granted FDA orphan designation as a treatment of soft tissue sarcoma, according to a post to the agency’s website.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LTRN:
- Lantern Pharma establishes India AI center to industrialize RADR platform
- Lantern Pharma announces LP-184 clinical trial met all primary endpoints